$DRMA
Dermata Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000165495423010487 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $910.0K $893.5K $1.118M
YoY Change 1.93% -20.08% 141.59%
% of Gross Profit
Research & Development $903.0K $838.9K $1.613M
YoY Change -41.87% -47.97% 85.95%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.812M $1.732M $1.613M
YoY Change 16.65% 7.43% 85.95%
Operating Profit -$1.812M -$1.732M -$2.731M
YoY Change -25.92% -36.55% 105.31%
Interest Expense $90.00K $31.05K $0.00
YoY Change 318.8% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.720M -$1.701M -$2.731M
YoY Change -29.06% -37.69% 105.03%
Income Tax
% Of Pretax Income
Net Earnings -$1.719M -$1.701M -$2.731M
YoY Change -29.09% -37.69% 105.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.54 -$0.63 -$3.90
Diluted Earnings Per Share -$0.54 -$0.63 -$243.9K
COMMON SHARES
Basic Shares Outstanding 3.189M shares 2.338M shares 9.227M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.630M $8.439M $10.63M
YoY Change -17.81% -20.6% 2387.8%
Cash & Equivalents $6.631M $8.439M $10.63M
Short-Term Investments
Other Short-Term Assets $690.0K $273.6K $398.5K
YoY Change -22.92% -31.36% -43.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.320M $8.713M $11.03M
YoY Change -18.44% -20.98% 869.9%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.383K $1.00 -$2.00
YoY Change -338400.0% -150.0%
TOTAL ASSETS
Total Short-Term Assets $7.320M $8.713M $11.03M
Total Long-Term Assets $3.383K $1.00 -$2.00
Total Assets $7.323M $8.713M $11.03M
YoY Change -18.4% -20.98% 869.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $474.5K $437.8K $608.8K
YoY Change -1.92% -28.09% -30.92%
Accrued Expenses $440.0K $245.1K $757.7K
YoY Change -56.89% -67.65% 29.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $920.0K $682.9K $1.366M
YoY Change -38.84% -50.03% -16.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $920.0K $682.9K $1.366M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $916.8K $682.9K $1.366M
YoY Change -39.05% -50.03% -16.81%
SHAREHOLDERS EQUITY
Retained Earnings -$51.25M -$49.53M -$41.50M
YoY Change 16.69% 19.36% 30.84%
Common Stock $319.00 $319.00 $1.010K
YoY Change -73.64% -68.42% 428.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.407M $8.030M $9.660M
YoY Change
Total Liabilities & Shareholders Equity $7.323M $8.713M $11.03M
YoY Change -18.4% -20.98% 869.9%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$1.719M -$1.701M -$2.731M
YoY Change -29.09% -37.69% 105.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.770M -$1.840M -$1.840M
YoY Change -30.89% 0.05% 103.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -40.00K 1.512M 4.276M
YoY Change -20100.0% -64.64%
NET CHANGE
Cash From Operating Activities -1.770M -1.840M -1.840M
Cash From Investing Activities
Cash From Financing Activities -40.00K 1.512M 4.276M
Net Change In Cash -1.810M -328.2K 2.437M
YoY Change -29.33% -113.47% -369.81%
FREE CASH FLOW
Cash From Operating Activities -$1.770M -$1.840M -$1.840M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2730573 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-4010096 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5516725 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2730573 usd
us-gaap Net Income Loss
NetIncomeLoss
-3941506 usd
us-gaap Net Income Loss
NetIncomeLoss
-5516725 usd
CY2022Q2 drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-3.90
drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-2.13
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6241294 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3208391 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1118021 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1978532 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2308334 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
245084 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
425932 usd
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3189034 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
838931 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001853816
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3189034 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
770115 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40739
dei Entity Registrant Name
EntityRegistrantName
DERMATA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-3218736
dei Entity Address Address Line1
EntityAddressAddressLine1
3525 Del Mar Heights Rd.
dei Entity Address Address Line2
EntityAddressAddressLine2
322
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
800-2543
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
dei Trading Symbol
TradingSymbol
DRMA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3189034 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8438530 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1732414 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
2730573 usd
us-gaap Operating Expenses
OperatingExpenses
4010096 usd
us-gaap Operating Expenses
OperatingExpenses
5516725 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1732414 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
31050 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
68590 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
CY2023Q2 drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-0.63
drma Net Loss Per Share Of Common Stock Basic And Diluted
NetLossPerShareOfCommonStockBasicAndDiluted
-9.02
CY2023Q2 drma Weighted Average Basic And Diluted Common Shares
WeightedAverageBasicAndDilutedCommonShares
2704987 usd
CY2022Q2 drma Weighted Average Basic And Diluted Common Shares
WeightedAverageBasicAndDilutedCommonShares
699679 usd
drma Weighted Average Basic And Diluted Common Shares
WeightedAverageBasicAndDilutedCommonShares
1850167 usd
drma Weighted Average Basic And Diluted Common Shares
WeightedAverageBasicAndDilutedCommonShares
611344 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
6021854 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131260 usd
CY2023Q1 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4174985 usd
CY2023Q1 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
153 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
40 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240142 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8088070 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
131177 usd
CY2023Q2 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
1512102 usd
CY2023Q2 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
34 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8030019 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10107104 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
531566 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2786151 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7852519 usd
CY2022Q2 drma Issuance Of Common Stock And Warrants Net Of Issuance Costs Amount
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostsAmount
4276365 usd
CY2022Q2 drma Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants Amount
IssuanceOfCommonStockUponExerciseOfPreFundedWarrantsAmount
87 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
55625 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
205947 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2730573 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
9659970 usd
us-gaap Profit Loss
ProfitLoss
3941506 usd
us-gaap Profit Loss
ProfitLoss
5516725 usd
us-gaap Share Based Compensation
ShareBasedCompensation
262437 usd
us-gaap Share Based Compensation
ShareBasedCompensation
474452 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-428843 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-426591 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-58924 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
93566 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-180848 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
74753 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
451508 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
1069362 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3489998 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4447363 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5687087 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4276365 usd
drma Proceeds From Pre Funded Warrants Exercises
ProceedsFromPreFundedWarrantsExercises
187 usd
drma Proceeds From Pre Funded Warrants Exercises
ProceedsFromPreFundedWarrantsExercises
87 usd
drma Payment For Fractional Shares In Reverse Stock
PaymentForFractionalSharesInReverseStock
40 usd
drma Payment For Fractional Shares In Reverse Stock
PaymentForFractionalSharesInReverseStock
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5687234 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4276452 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2197236 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-170911 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6241294 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10798806 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8438530 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10627895 usd
CY2021Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
160714 shares
CY2023Q2 drma Class Of Warrant Or Right Exercise Price Of Warrants Or Right
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRight
112.00
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
8400000 usd
CY2023Q2 drma Accumulated Deficit
AccumulatedDeficit
-49500000 usd
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
3500000 usd
CY2022 us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
8800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The Company’s financial statements are prepared in accordance with GAAP. The preparation of the Company’s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and the estimated fair values of equity instruments. Management evaluates its estimates on an ongoing basis. The Company bases its estimates on various assumptions that it believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1701364 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2730573 usd
us-gaap Net Income Loss
NetIncomeLoss
-3941506 usd
us-gaap Net Income Loss
NetIncomeLoss
-5516725 usd
CY2023Q2 drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
2704987 shares
CY2022Q2 drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
699679 shares
drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
1850167 shares
drma Weighted Average Number Of Basic And Diluted Shares Outstanding
WeightedAverageNumberOfBasicAndDilutedSharesOutstanding
611344 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.63
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.02
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4745629 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
499684 shares
CY2023Q2 drma Proceeds Cash From Pipe
ProceedsCashFromPipe
1500000 usd
CY2023Q2 drma Underwriters Discounts And Offering Expenses In Pipe
UnderwritersDiscountsAndOfferingExpensesInPipe
300000 usd
drma Warrant Reduced Description
WarrantReducedDescription
from $21.20 to $2.82 per share upon closing of the March 2023 Offering
drma Reverse Stock Split
ReverseStockSplit
1-for-16
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0.0001
CY2023Q1 drma Common Stock Share Issued
CommonStockShareIssued
85000 shares
CY2023Q1 drma Increasing Shares Authorized For Issuance
IncreasingSharesAuthorizedForIssuance
1533123 shares
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
drma Warrants Exercised During Period Share
WarrantsExercisedDuringPeriodShare
1533123 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4643555 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
437102 shares

Files In Submission

Name View Source Status
0001654954-23-010487-index-headers.html Edgar Link pending
0001654954-23-010487-index.html Edgar Link pending
0001654954-23-010487.txt Edgar Link pending
0001654954-23-010487-xbrl.zip Edgar Link pending
drma-20230630.xsd Edgar Link pending
drma_10q.htm Edgar Link pending
drma_ex311.htm Edgar Link pending
drma_ex312.htm Edgar Link pending
drma_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
drma-20230630_cal.xml Edgar Link unprocessable
drma-20230630_lab.xml Edgar Link unprocessable
drma-20230630_def.xml Edgar Link unprocessable
drma-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drma_10q_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending